MX393281B - Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino. - Google Patents

Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.

Info

Publication number
MX393281B
MX393281B MX2019015527A MX2019015527A MX393281B MX 393281 B MX393281 B MX 393281B MX 2019015527 A MX2019015527 A MX 2019015527A MX 2019015527 A MX2019015527 A MX 2019015527A MX 393281 B MX393281 B MX 393281B
Authority
MX
Mexico
Prior art keywords
compositions
conjugates
platinum
texafirin
strength
Prior art date
Application number
MX2019015527A
Other languages
English (en)
Other versions
MX2019015527A (es
Inventor
Gregory Thiabaud
Jonathan Arambula
Jonathan L Sessler
Zahid H Siddik
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2019015527A publication Critical patent/MX2019015527A/es
Publication of MX393281B publication Critical patent/MX393281B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción se refiere a composiciones y conjugados unidos a platino (IV) y texafirina que comprenden una texafirina y un agente de platino (IV). La presente descripción también proporciona composiciones farmacéuticas de los conjugados y composiciones. Además, en la presente se proporcionan métodos para utilizar los presentes compuestos en el tratamiento de cáncer tal como un cáncer resistente a platino.
MX2019015527A 2014-06-11 2015-06-11 Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino. MX393281B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462010841P 2014-06-11 2014-06-11
US201562135502P 2015-03-19 2015-03-19
PCT/US2015/035229 WO2015191797A1 (en) 2014-06-11 2015-06-11 Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance

Publications (2)

Publication Number Publication Date
MX2019015527A MX2019015527A (es) 2022-06-17
MX393281B true MX393281B (es) 2025-03-24

Family

ID=54834283

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019015527A MX393281B (es) 2014-06-11 2015-06-11 Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
MX2016016419A MX370673B (es) 2014-06-11 2015-06-11 Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016016419A MX370673B (es) 2014-06-11 2015-06-11 Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.

Country Status (13)

Country Link
US (3) US10406167B2 (es)
EP (1) EP3154541A4 (es)
JP (3) JP7304128B2 (es)
KR (1) KR102412203B1 (es)
CN (2) CN116178456A (es)
AU (1) AU2015274589B2 (es)
BR (1) BR112016029024A8 (es)
CA (1) CA2950305C (es)
IL (1) IL249453B (es)
MX (2) MX393281B (es)
SG (1) SG11201610306RA (es)
WO (1) WO2015191797A1 (es)
ZA (1) ZA201608194B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950305C (en) 2014-06-11 2023-03-14 Board Of Regents, The University Of Texas System Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance
WO2018067551A1 (en) * 2016-10-03 2018-04-12 Board Of Regents, The University Of Texas System Texaphyrin and antitumor antibiotic conjugates
CN106543234B (zh) * 2016-10-14 2019-04-09 昆明理工大学 以饱和链为桥的手性双核铂配合物及其制备方法和应用
CN108732147B (zh) * 2018-04-23 2021-01-19 南京邮电大学 基于fret效应探测细胞凋亡过程的方法
EP3986466A1 (en) * 2019-06-18 2022-04-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. Site-specific, kinetically inert conjugation of labels and/or carriers to target molecules such as his-tagged proteins via metal complex reagents
CN116264824A (zh) 2020-08-14 2023-06-16 德克萨斯大学系统董事会 用于锰化学疗法、光声成像和光热疗法的德克萨卟啉衍生物
CN114539320B (zh) * 2020-11-25 2026-01-27 北京大学 辐射激活的四价铂配合物及其用途
CN113292578A (zh) * 2021-05-21 2021-08-24 弗兰克·杰瑞·拉罗德 一种texaphyrin-叶酸螯合物及其制备方法与应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265823A (en) 1979-01-04 1981-05-05 Robert E. Kosinski Aurothiosteroids
US4980473A (en) 1985-01-18 1990-12-25 The Trustees Of Columbia University In The City Of New York Chemical probes for left-handed DNA and chiral metal complexes as Z-specific anti-tumor agents
JPS62207283A (ja) 1986-03-07 1987-09-11 Yoshinori Kitani 新規な白金錯体
US5072011A (en) 1988-02-02 1991-12-10 Johnson Matthey, Inc. Pt(IV) complexes
US4870208A (en) 1988-06-03 1989-09-26 Monsanto Company Asymmetric hydrogenolysis of epoxides
US5599923A (en) 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5162509A (en) 1989-03-06 1992-11-10 Board Of Regents, The University Of Texas System Process for preparing expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5272142A (en) 1989-03-06 1993-12-21 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles and methods for treating tumors
US4935498A (en) 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5252720A (en) 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US5252270A (en) 1990-12-20 1993-10-12 Basf Aktiengesellschaft Method of forming foam moldings having varied density regions
US5578498A (en) 1991-05-22 1996-11-26 Behringwerke Ag Metal chelate containing compositions for use in chemiluminescent assays
US5624919A (en) 1993-09-14 1997-04-29 The University Of Vermont And State Agricultural College Trans platinum (IV) complexes
US5409915A (en) 1993-09-14 1995-04-25 The University Of Vermont And State Agricultural College Bis-platinum (IV) complexes as chemotherapeutic agents
US5533354A (en) 1994-09-20 1996-07-09 Texan Corporation Personal comfort apparatus
US5633354A (en) 1994-09-21 1997-05-27 Pharmacyclics, Inc. Phosphoramidite derivatives of texaphyrins
US5756726A (en) 1995-06-02 1998-05-26 Pharmacyclics, Inc. Methods of producing singlet oxygen using compounds having improved functionalization
US5776925A (en) 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
US5955586A (en) 1996-03-22 1999-09-21 Sessler; Jonathan L. Highly boronated derivatives of texaphyrins
AU7711096A (en) 1996-12-03 1998-06-29 Rijsuniversiteit Utrecht Cisplatinum comprising pharmaceutical
KR20010052616A (ko) * 1998-06-05 2001-06-25 파라비 레이 텍사피린 콘쥬게이트 및 그 용도
AU1234001A (en) 1999-10-29 2001-05-14 Board Of Regents, The University Of Texas System Conjugate compounds for treating atheroma, tumors and other neoplastic tissue
AU2001255125A1 (en) 2000-04-10 2001-10-23 National University Of Singapore Gold complexes
WO2002017925A1 (en) 2000-08-30 2002-03-07 Pharmacyclics, Inc. Non-symmetric tripyrrannes in the synthesis of novel macrocycles
US7479557B2 (en) 2004-06-10 2009-01-20 Agency For Science, Technology +Research DNA threading intercalators
FR2873037B1 (fr) 2004-07-13 2008-04-11 Univ Pasteur Methodes et compositions pour le traitement de cancers
CZ2004964A3 (cs) 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
WO2006078875A2 (en) * 2005-01-19 2006-07-27 Pharmacyclics, Inc. A method for treating neurologic diseases
US8246967B2 (en) 2005-08-02 2012-08-21 Macdonnell Frederick M Compounds with modifying activity enhanced under hypoxic conditions
US20070072838A1 (en) 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
TW200728315A (en) 2005-12-06 2007-08-01 Nippon Chemical Ind Phosphorus transition-metal complex, method of producing the same, and anticancer agent forming the same
US20120164230A1 (en) 2007-05-08 2012-06-28 Rodney Feazell Soluble Nanoparticles as Delivery Systems for Prodrugs
SI2173337T1 (sl) 2007-08-06 2014-10-30 Ohio University Fosfaplatini in njihova uporaba pri zdravljenju vrst raka, odpornih proti cisplatinu in karboplatinu
CN101125865B (zh) 2007-09-29 2010-09-08 广东药学院 手性钌配合物及其作为抗肿瘤药物的应用
WO2010027428A1 (en) 2008-08-26 2010-03-11 Massachusetts Institute Of Technology Platinum ( iv) complexes for use in dual mode pharmaceutical therapy
MX2011009749A (es) 2009-03-20 2012-01-20 Univ Padova Complejos de oro (iii) con oligopeptidos funcionalizados con donadores de azufre y su uso como agentes antitumorales.
CN102725298B (zh) 2009-10-28 2015-07-01 香港大学 作为组蛋白脱乙酰酶抑制剂的羟基取代的金(iii)卟啉络合物
CN102058576B (zh) 2010-12-28 2012-07-25 中国科学院深圳先进技术研究院 顺铂前体药物及其制备方法、核壳纳米颗粒及其制备方法
WO2012138988A2 (en) 2011-04-07 2012-10-11 The Research Foundation Of The City University Of New York Organometallic anti-cancer complexes
MX2013015340A (es) 2011-06-21 2014-05-28 Brigham & Womens Hospital Composiciones y metodos para el tratamiento de cancer.
JP5179628B2 (ja) 2011-07-15 2013-04-10 ユニーテック株式会社 ４価白金錯体及びそれを含む医薬組成物
CN102408452B (zh) * 2011-12-13 2014-09-03 中山大学 四吡啶基卟啉桥联十字形四核铂配合物及其制备方法和抗肿瘤活性
US8729286B2 (en) 2012-05-10 2014-05-20 Massachusetts Institute Of Technology Platinum compounds as treatment for cancers, and related methods, kits, and compositions
US8828984B2 (en) 2012-11-19 2014-09-09 The University Of Hong Kong Gold(III) complexes containing N-heterocyclic carbene ligand, synthesis, and their applications in cancer treatment and thiol detection
WO2014160216A2 (en) 2013-03-13 2014-10-02 Massachusetts Institute Of Technology Dual targeting anticancer agents
US9593139B2 (en) 2013-04-05 2017-03-14 Massachusetts Institute Of Technology Compositions, methods, and kits comprising platinum compounds associated with a ligand comprising a targeting moiety
CA2950305C (en) 2014-06-11 2023-03-14 Board Of Regents, The University Of Texas System Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance

Also Published As

Publication number Publication date
MX2019015527A (es) 2022-06-17
EP3154541A4 (en) 2017-12-20
AU2015274589A1 (en) 2016-12-15
JP2017519004A (ja) 2017-07-13
MX2016016419A (es) 2017-04-06
US20200069698A1 (en) 2020-03-05
CA2950305C (en) 2023-03-14
ZA201608194B (en) 2023-05-31
NZ726729A (en) 2023-08-25
IL249453B (en) 2021-01-31
CA2950305A1 (en) 2015-12-17
US11389459B2 (en) 2022-07-19
BR112016029024A8 (pt) 2021-07-20
JP2021102616A (ja) 2021-07-15
JP2023078171A (ja) 2023-06-06
AU2015274589B2 (en) 2020-12-03
WO2015191797A1 (en) 2015-12-17
KR102412203B1 (ko) 2022-06-23
US20170246182A1 (en) 2017-08-31
JP7304128B2 (ja) 2023-07-06
US20230113036A1 (en) 2023-04-13
CN116178456A (zh) 2023-05-30
CN106572991A (zh) 2017-04-19
US12472187B2 (en) 2025-11-18
KR20170016933A (ko) 2017-02-14
IL249453A0 (en) 2017-02-28
US10406167B2 (en) 2019-09-10
SG11201610306RA (en) 2017-01-27
EP3154541A1 (en) 2017-04-19
MX370673B (es) 2019-12-19
BR112016029024A2 (pt) 2017-08-22

Similar Documents

Publication Publication Date Title
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
MX393281B (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
TW201613901A (en) New compounds
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
PH12017500803A1 (en) Anti-pd-1 antibodies
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
GB201209613D0 (en) New compounds
MX2016008448A (es) Conjugados de var2csa-farmaco.
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
MX378273B (es) Compuestos activos hacia bromodominios.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
EA201590987A1 (ru) Соединения и способы их применения
MX386859B (es) Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos.
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
EA201590997A1 (ru) Соединения и способы их применения
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
MX2018005544A (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer.
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
CL2015002897A1 (es) Inhibidores de bace1